Longeveron Mesenchymal Stem Cells

BIOLOGICAL2 trials

Sponsors

Longeveron Inc.

Conditions

Alzheimer's DiseaseHLHS

Phase 1

Lomecel-B Infusion Versus Placebo in Patients With Alzheimer's Disease

CompletedNCT02600130

Longeveron Inc.Alzheimer's Disease

Start: 2016-10-10End: 2021-09-30Updated: 2021-12-14

Lomecel-B Delivered During Stage II Surgery for Hypoplastic Left Heart Syndrome (ELPIS)

Longeveron Inc.HLHS

Start: 2018-02-21End: 2025-12-31Updated: 2023-10-04

Related Papers

Statistical modeling of extracellular vesicle cargo to predict clinical trial outcomes for hypoplastic left heart syndrome.

2023-09-212 citations

Intramyocardial cell-based therapy with Lomecel-B during bidirectional cavopulmonary anastomosis for hypoplastic left heart syndrome: the ELPIS phase I trial

European Heart Journal Open2023-01-1112 citations

Safety and efficacy of Lomecel‐B in patients with mild Alzheimer’s disease: Results of a double‐blinded, randomized, placebo‐controlled phase 1 clinical trial

Alzheimer s & Dementia2021-12-01

Clinical evaluation of allogeneic mesenchymal stem cells for Alzheimer's disease

Alzheimer s & Dementia2020-12-012 citations

P2‐039: PROGRESS OF THE PHASE I CLINICAL TRIAL TO EVALUATE LONGEVERON ALLOGENEIC MESENCHYMAL STEM CELLS (LMSCS) AS A POTENTIAL THERAPEUTIC FOR ALZHEIMER'S DISEASE

Alzheimer s & Dementia2019-07-011 citations